CLS: TRANBERG[®] Thermal Therapy System installed at Andros Clinics for Launch of Ultrasound-Guided Focal Laser Ablation Program in The Netherlands

The first three patients have also been successfully treated at Andros Clinics, marking an important clinical milestone in CLS's strategy to expand the adoption of FLA across Europe.

Treatment of prostate cancer with radical prostatectomy is frequently associated with urinary incontinence and erectile dysfunction, which can significantly affect a patient's quality of life. FLA offers a more favorable functional outcome in this regard and is a treatment option for patients with localized, low to intermediate risk prostate cancer.

"This is a significant step forward for focal therapy and for patient choice. FLA is an attractive treatment option for appropriately selected patients who want a minimally invasive approach with minimal side effects. The TRANBERG System integrates seamlessly into our ultrasound-guided workflow, with the first procedures completed successfully. We are excited to further develop our focal therapy program with this technology and through collection of data in our recently approved patient registry." Commented Mr. Domien Debruyne, CEO of Andros Clinics.

"We are keen to support Andros Clinics in the launch of their focal laser ablation program for localized prostate cancer with the TRANBERG System. This installation highlights MTEC Company's commitment to enabling the clinical adoption of meaningful, minimally invasive prostate cancer therapies at leading urology centers, in close partnership with CLS and key opinion leaders." said Eric Girard, CEO, MTEC Company

"We are very pleased to see the TRANBERG System in clinical use at Andros Clinics, a leading center for men's health in the Netherlands. Their adoption of our technology reinforces the growing interest in minimally invasive focal therapies for patients with localized prostate cancer. Together with our partner MTEC Company, we look forward to supporting Andros Clinics in making this treatment available to more patients." Commented Dan J Mogren, CEO of CLS.

About TRANBERG® Thermal Therapy System

The TRANBERG System is designed for predictable and controlled thermal ablation of soft tissue. In prostate applications, it allows clinicians to target and ablate cancerous lesions with precision while sparing surrounding tissues - supporting faster recovery, preservation of function, and high patient satisfaction.

About Andros Clinics

Andros Clinics is a leading specialist center for men's health in the Netherlands, providing advanced diagnostic and therapeutic services for prostate disease and other urogenital conditions. More information: https://www.andros.nl

About MTEC Company

MTEC Company specializes in the distribution of cutting-edge medical technologies, with a focus on solutions that improve clinical outcomes and patient quality of life. More information: https://www.mtec-company.com

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-post: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG^® Thermal Therapy System and ClearPoint Prism^® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se